Flu Vaccine for the 2011-2012 Season Approved

On Monday, the U.S. Food and Drug Administration (FDA) said it had approved the formulation for the 2011-2012 vaccine [1]. This year’s formulation is designed to protect against all three strains included in last years vaccine. Nevertheless, if you received a flu shot last year, you should still get vaccinated again this year: immunity to influenza viruses from vaccination declines over time and may be too low to provide protection after a year.

Flu vaccine

The Flu and Your Health

It’s the gift-giving season. However, there’s one gift this time of year you don’t want to give or get: the flu virus. Flu season runs from November to April, with most cases occurring between late December and early March. About 10-20% of people get the flu every winter [1]. In children, the number is even higher with up to 40% of children becoming clinically ill due to the influenza virus.

NIAID Trial of 2009 H1N1 Influenza Vaccine Enrolling HIV-Positive Adults

HIV-infected adults currently are being recruited to participate in a clinical trial of 2009 H1N1 influenza vaccine. The study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, will enroll approximately 240 men and women between the ages of 18 and 64.

Safety and Distribution of the H1N1 Influenza Vaccine

Know What to Do About the Flu is a webcast series launched by the U.S. Department of Health and Human Services (HHS) to hlep distribute timely and accurate information about the flu. Their goal is to distribute the latest facts and medical guidances so we can all be more effective in combating the spread of the flu and be better prepared should our families, our communities or our workplaces become affected.

In this edition, moderator Lark McCarthy discusses the level of testing prior to the H1N1 influenza A vaccine distribution and the subsequent monitoring that’s planned during and after the phases of distribution with Dr. Bruce Gellin, Director of the National Vaccine Program Office (NVPO) within the HHS, Dr. Jesse Goodman, acting chief scientist with the U.S. Food and Drug Administration (FDA), Dr. Harvey Fineberg, President of the Institute of Medicine (IOM) and Dr. Anne Schuchat, Director of the Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC).

Details of Critically Ill Patients with H1N1 in Mexico and Canada

Two studies, which are available online as early release articles and will be published in the November edition of the Journal of the American Medical Association (JAMA), detail the characteristics, treatment and outcomes of critically ill patients with H1N1 in Mexico and Canada [1-2].

respiratory-ventilation

Although the death rate in each of the studies is quite different, it nonetheless is as high or higher than that of seasonal flu. Furthermore, although seasonal flu typically affects people of older age — the average annual rate of influenza-associated hospitalizations over the last 20 years for people age 65 and older is 70% [3] — these studies show that H1N1 is striking many who are much younger. In both studies, the majority of critically ill patients with influenza A H1N1 had rapidly progressive respiratory failure and required mechanical ventilation.